Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.

Abstract

IMPORTANCE OF THE FIELD:

Tumor associated antigens (TAAs) offer specific targets for developing cancer immunotherapies. In particular, viral vectors encoding transgenic TAAs have been used in recent vaccination strategies. Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy.

AREAS COVERED IN THIS REVIEW:

The lines of evidence over the past two decades leading to the development of Ad-WT1 immunotherapy are reviewed, including preclinical studies and clinical trials using WT1-based vaccines and TAA-expressing adenoviral vectors for antitumor therapy.

WHAT THE READER WILL GAIN:

The fundamental immunogenic properties of WT1-based vaccines are detailed, as well as the recent progress in using adenoviral vectors for eliciting a TAA-specific immune response. The reader will also gain an understanding of the evidence supporting Ad-WT1 antitumor therapy in vivo.

TAKE HOME MESSAGE:

Ad-WT1 elicits a potent CD4(+) and CD8(+) T cell immune response and can effectively inhibit tumor growth in vivo, thus making it an important potential cancer therapy worthy of future investigation.

• Authors: Jeffrey M Clarke, Michael A Morse, H Kim Lyerly, Timothy Clay, Tayuka Osada
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 10 Issue 6 Pg. 875-83 (Jun 2010) ISSN: 1744-7682 [Electronic] England
• PMID: 20380487 (Publication Type: Journal Article, Review)

Chemical References

• Viral Vaccines

Topics

• Adenoviridae (immunology)
• Animals
• Clinical Trials as Topic
• Genes, Wilms Tumor (physiology)
• Humans
• Neoplasms (genetics, therapy)
• Viral Vaccines (therapeutic use)